[Unicocell] Application for Clinical Trial Design Change for ELIXCYTE
NQ Score
51/100
N1 Content Completeness
10
AI Summary (NQ-processed)
Unicocell announced on May 29, 2026, that it has applied to the Ministry of Health and Welfare to change the design of its Phase 3 clinical trial for the knee osteoarthritis drug ELIXCYTE. The change aims to add an interim analysis to obtain key efficacy data earlier. Enrollment was completed in November 2025.
AI Analysis
Frequently Asked Questions
- Q: What is the status of the ELIXCYTE clinical trial by Unicocell?
- A: Phase 3 enrollment is complete, and they are applying for a change in trial design.